MediGene, 4SC, Pieris - the news flow of these Bavarian biotech companies located around Munich city is producing the headline of the last few days. These companies show the entire range of innovative Munich biotechs that are increasingly able to address international investors again.
From immunotherapy (www.medigene.com ), new Proteinscaffolds (www.pieris.com ) to small molecules that take into account the genetic profile of the patient (epigenetic biomarkers; www.4sc.com ) a whole range of state-of- the-art technologies showcases high-flying in front of a spolied investor community.
Medigene was able to raise €46m, 4SC: €29m and Pieris got a swig of NASDAQ with $28m!
Keep on going!